Holen Sie sich die Stockscreener-App
499.88
5.73%
27.08
Handel nachbörslich:
499.88
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$472.80
Offen:
$483
24-Stunden-Volumen:
1.67M
Relative Volume:
1.63
Marktkapitalisierung:
$128.48B
Einnahmen:
$10.34B
Nettoeinkommen (Verlust:
$-489.90M
KGV:
37.50
EPS:
13.33
Netto-Cashflow:
$-1.43B
1W Leistung:
+6.28%
1M Leistung:
+9.79%
6M Leistung:
+24.63%
1J Leistung:
+32.88%
1-Tages-Spanne:
$474.00
$503.20
1-Wochen-Bereich:
$463.14
$503.20
52-Wochen-Spanne:
$341.90
$510.63
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But Valuation Reflects It (VRTX) - Seeking Alpha
Vertex Offers A Surprise Entry As Non-Opioid Pain Drug Looms - Investor's Business Daily
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $586.00 Price Target at UBS Group - MarketBeat
Vertex shares up after full-year product revenue guidance boost - Pharmaceutical Technology
Vertex Pharmaceuticals' (VRTX) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Royal Bank of Canada Increases Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $451.00 - MarketBeat
Vertex's Casgevy breaks ground with 1st commercial patient infusions as company readies another major launch for 2025 - FiercePharma
JPMorgan Chase & Co. Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised - Yahoo Finance Australia
Morgan Stanley Raises Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $476.00 - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Issues Earnings Results - MarketBeat
Investors reevaluate this year’s obesity darling - STAT
5 Top Stocks to Buy in November - The Motley Fool
Vertex Pharma reports Q3 2024 net income of $1.04bn - World Pharmaceutical Frontiers
Vertex tops Q3 forecast on strength of cystic fibrosis sales, raises full-year revenue guidance - PharmaLive
Vertex (VRTX) PT Raised to $451 at RBC Capital - StreetInsider.com
Vertex ups guidance again as results exceed estimates - The Pharma Letter
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by QRG Capital Management Inc. - MarketBeat
Earnings call: Vertex Pharmaceuticals Q3 2024 revenue climbs 12% - Investing.com
Earnings call: Vertex Pharmaceuticals Q3 2024 revenue climbs 12% By Investing.com - Investing.com UK
Vertex Pharmaceuticals Inc (VRTX) Q3 2024 Earnings Call Highligh - GuruFocus.com
Vertex Pharmaceuticals Inc (VRTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance UK
Vertex Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript - Yahoo Finance
Vertex Reports Third Quarter 2024 Financial Results - BioSpace
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength - MSN
Vertex ups revenue guidance, eyes new 'multibillion-dollar franchise' - The Business Journals
Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms - MSN
Vertex Pharmaceuticals Tops Q3 Estimates - The Motley Fool
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Vertex: Q3 Earnings Snapshot - San Antonio Express-News
Vertex raises 2024 product revenue outlook following Q3 beats - Seeking Alpha
Vertex Pharmaceuticals Inc. Q3 Profit Increases, Beats Estimates - Nasdaq
Q3 2024 Vertex Pharmaceuticals Inc Earnings Call Transcript - GuruFocus.com
Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings - MarketWatch
Vertex Beats Quarterly Estimates As Pain Drug Looms - Investor's Business Daily
Vertex Pharmaceuticals Ups Revenue Forecast On Cystic Fibrosis Demand - Finimize
Vertex Pharma (VRTX) Tops Q3 EPS by 30c; raises guidance - StreetInsider.com
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength | Today News - Mint
Vertex Pharmaceuticals Q3 24 Earnings Conference Call At 4:30 PM ET - Nasdaq
Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts? - Benzinga
Janney Montgomery Scott LLC Lowers Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
US Bancorp DE Acquires 2,273 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
F M Investments LLC Lowers Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
9 Best Biotech Stocks Of November 2024 - Forbes
Vertex Pharma (VRTX) November 11 weekly option implied volatility into quarter results - StreetInsider.com
Vertex Pharma (VRTX) November 11 weekly 475 straddle priced into quarter results - StreetInsider.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Pinnacle Associates Ltd. - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - MSN
HM Payson & Co. Has $3.29 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.07%
1.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):